Elanco Animal Health Incorporated $ELAN Position Lessened by First Trust Advisors LP

First Trust Advisors LP lowered its stake in shares of Elanco Animal Health Incorporated (NYSE:ELAN) by 30.3% in the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 1,743,289 shares of the company’s stock after selling 757,533 shares during the quarter. First Trust Advisors LP owned approximately 0.35% of Elanco Animal Health worth $35,110,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently added to or reduced their stakes in the stock. Primecap Management Co. CA lifted its stake in Elanco Animal Health by 3.1% in the second quarter. Primecap Management Co. CA now owns 51,766,814 shares of the company’s stock valued at $739,230,000 after buying an additional 1,543,279 shares during the last quarter. Vanguard Group Inc. grew its position in shares of Elanco Animal Health by 1.6% during the third quarter. Vanguard Group Inc. now owns 48,586,708 shares of the company’s stock worth $978,536,000 after acquiring an additional 759,623 shares during the last quarter. Dimensional Fund Advisors LP grew its position in shares of Elanco Animal Health by 8.6% during the third quarter. Dimensional Fund Advisors LP now owns 24,708,676 shares of the company’s stock worth $497,610,000 after acquiring an additional 1,962,276 shares during the last quarter. Brandes Investment Partners LP increased its holdings in shares of Elanco Animal Health by 11.3% in the 2nd quarter. Brandes Investment Partners LP now owns 8,100,322 shares of the company’s stock worth $115,673,000 after acquiring an additional 820,901 shares during the period. Finally, Goldman Sachs Group Inc. increased its holdings in shares of Elanco Animal Health by 104.5% in the 1st quarter. Goldman Sachs Group Inc. now owns 4,787,394 shares of the company’s stock worth $50,268,000 after acquiring an additional 2,445,872 shares during the period. 97.48% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

A number of research analysts have issued reports on ELAN shares. UBS Group reissued a “buy” rating on shares of Elanco Animal Health in a research note on Tuesday. Argus upgraded shares of Elanco Animal Health from a “hold” rating to a “buy” rating and set a $25.00 price target on the stock in a research note on Wednesday, November 19th. Morgan Stanley lifted their price target on Elanco Animal Health from $22.00 to $24.00 and gave the company an “equal weight” rating in a report on Wednesday, February 25th. Wall Street Zen upgraded Elanco Animal Health from a “buy” rating to a “strong-buy” rating in a research report on Monday, January 19th. Finally, KeyCorp increased their price objective on Elanco Animal Health from $27.00 to $29.00 and gave the stock an “overweight” rating in a report on Wednesday, February 25th. One investment analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $27.67.

Elanco Animal Health Stock Performance

Shares of ELAN opened at $22.64 on Friday. The firm has a 50-day moving average price of $24.51 and a 200 day moving average price of $22.15. The firm has a market capitalization of $11.26 billion, a PE ratio of -47.17, a P/E/G ratio of 2.99 and a beta of 1.83. The company has a quick ratio of 1.08, a current ratio of 2.17 and a debt-to-equity ratio of 0.60. Elanco Animal Health Incorporated has a 52-week low of $8.02 and a 52-week high of $27.72.

Elanco Animal Health (NYSE:ELAN) last released its quarterly earnings results on Tuesday, February 24th. The company reported $0.13 EPS for the quarter, topping analysts’ consensus estimates of $0.11 by $0.02. The company had revenue of $1.14 billion for the quarter, compared to the consensus estimate of $1.09 billion. Elanco Animal Health had a negative net margin of 4.92% and a positive return on equity of 7.16%. Elanco Animal Health’s revenue was up 12.2% on a year-over-year basis. During the same period in the previous year, the firm earned $0.14 EPS. Elanco Animal Health has set its Q1 2026 guidance at 0.330-0.36 EPS and its FY 2026 guidance at 1.000-1.060 EPS. On average, sell-side analysts anticipate that Elanco Animal Health Incorporated will post 0.91 earnings per share for the current fiscal year.

About Elanco Animal Health

Elanco Animal Health Inc is a global leader in animal health dedicated to improving food and companion animal well-being. The company develops, manufactures and markets a range of products, including parasiticides, vaccines, antibiotics and feed additives designed to prevent and treat disease in livestock and pets. Elanco’s portfolio spans both food-producing animals—such as cattle, swine, poultry and aquaculture—and companion animals, with offerings that support parasite control, pain management and infectious disease prevention.

Originally founded as the animal health division of Eli Lilly and Company in the mid-20th century, Elanco was spun off into an independent publicly traded company in 2018.